Weekly Topotecan Therapy in Patients With Ovarian Cancer

• Status: Terminated
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Treatments: Topotecan

Criteria

Inclusion Criteria:

• Patients must have a histopathologic diagnosis of epithelial ovarian cancer.

• Patients must have completed front-line chemotherapy and be clinically NED (CA 125 <35, negative CT scan, negative physical exam).

• Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative).

• Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy.

• Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy.

• Patients may have had only one prior chemotherapy regimen.

Exclusion Criteria:

• Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer.

• Patients who are pregnant or breast-feeding.